2,778,200 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC acquired a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,778,200 shares of the biotechnology company's stock, valued at approximately $6,112,000. Heron Therapeutics makes up about 2.5% of AIGH Capital Management LLC's holdings, making the stock its 14th biggest holding. AIGH Capital Management LLC owned approximately 1.82% of Heron Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Wealth Alliance LLC acquired a new stake in Heron Therapeutics during the 1st quarter worth about $70,000. New York State Common Retirement Fund grew its holdings in shares of Heron Therapeutics by 32.7% during the first quarter. New York State Common Retirement Fund now owns 1,752,924 shares of the biotechnology company's stock worth $3,856,000 after buying an additional 431,918 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in shares of Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 4,619 shares during the period. Palisade Capital Management LP increased its holdings in Heron Therapeutics by 34.7% in the 1st quarter. Palisade Capital Management LP now owns 5,286,931 shares of the biotechnology company's stock valued at $11,631,000 after purchasing an additional 1,360,542 shares in the last quarter. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Heron Therapeutics in the first quarter valued at approximately $273,000. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock traded up $0.02 on Tuesday, hitting $1.94. 336,770 shares of the company's stock were exchanged, compared to its average volume of 2,135,534. The stock has a market capitalization of $295.20 million, a PE ratio of -32.25 and a beta of 1.18. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.32. The company has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $2.00.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. On average, analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HRTX has been the topic of a number of research reports. HC Wainwright began coverage on shares of Heron Therapeutics in a research report on Monday, June 9th. They set a "buy" rating and a $6.00 target price on the stock. Wall Street Zen raised Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Needham & Company LLC reissued a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.